• Aucun résultat trouvé

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial.

N/A
N/A
Protected

Academic year: 2021

Partager "Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial."

Copied!
15
0
0

Texte intégral

Loading

Figure

Table 2 reports the correlation between each single marker and DFS. The 12 proteins associated with shorter DFS in univariate analysis (negativity of BCL2, CK8/18, ER, GATA3, MUC1, PR, and TAU, and  positiv-ity of Aurora A, HER2, Ki67, P-Cadherin, and P53)
Table 2 Univariate and multivariate analyses of 34 antibodies for DFS Marker Category N (%) Univariate Multivariate Unadjusted Hazard Ratio (95%CI) P-value (Log-rank) Adjusted Hazard Ratio(95%CI) P-value(Wald) AF6 Neg
Table 3 Multivariate analyses of 34 antibodies for inter- inter-action with chemotherapy arm (Continued)
Figure 2 Adjusted hazard ratios associated with docetaxel addition. Forest plots showing the adjusted hazard ratios associated with docetaxel addition according to expression of 34 proteins.

Références

Documents relatifs

Prognostic fac- tors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo- adjuvant chemotherapy followed by interval debulking surgery: